Danila, Daniel C.

Publications

Sort by

Co-Author Network

selected publications

Reply by Authors. The Journal of urology. 2020 Article GET IT
Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. The Journal of urology. 2020 Academic Article GET IT
Times cited: 9
Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular pharmaceutics. 2019 Academic Article GET IT
Times cited: 27
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 39
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 182
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 413
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 1692
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urologic oncology. 2017 Academic Article GET IT
Times cited: 16
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 147
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2016 Academic Article GET IT
Times cited: 50
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA oncology. 2016 Academic Article GET IT
Times cited: 526
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. Cancer journal (Sudbury, Mass.). 2016 Academic Article GET IT
Times cited: 60
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European urology. 2016 Academic Article GET IT
Times cited: 125
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 325
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 1152
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British journal of cancer. 2013 Academic Article GET IT
Times cited: 75
Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay. Translational oncology. 2013 Academic Article GET IT
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. European urology. 2013 Academic Article GET IT
Times cited: 62
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. The oncologist. 2013 Academic Article GET IT
Times cited: 156
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 96
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer research. 2012 Academic Article GET IT
Times cited: 175
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer journal (Sudbury, Mass.). 2011 Information Resource GET IT
Times cited: 74
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European urology. 2011 Academic Article GET IT
Times cited: 174
Circulating tumor cells as biomarkers in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Information Resource GET IT
Times cited: 206
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (London, England). 2010 Academic Article GET IT
Times cited: 962
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 382
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 364
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 179
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clinical chemistry. 2009 Academic Article GET IT
Times cited: 121
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 508
Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leukemia & lymphoma. 2007 Article GET IT
Times cited: 8
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 288
A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. The Journal of clinical endocrinology and metabolism. 2003 Academic Article GET IT
Times cited: 326
Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells. The Journal of clinical endocrinology and metabolism. 2002 Academic Article GET IT
Times cited: 19
Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. The Journal of clinical endocrinology and metabolism. 2002 Academic Article GET IT
Times cited: 129
Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. The Journal of clinical endocrinology and metabolism. 2001 Academic Article GET IT
Times cited: 76
Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Molecular endocrinology (Baltimore, Md.). 2000 Academic Article GET IT
Primary medical therapy of micro- and macroprolactinomas in men. The Journal of clinical endocrinology and metabolism. 2000 Academic Article GET IT
Times cited: 121
A human pituitary tumor-derived folliculostellate cell line. The Journal of clinical endocrinology and metabolism. 2000 Academic Article GET IT
Times cited: 36
Activin effects on neoplastic proliferation of human pituitary tumors. The Journal of clinical endocrinology and metabolism. 2000 Academic Article GET IT
Times cited: 47
Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas. The Journal of clinical endocrinology and metabolism. 1999 Academic Article GET IT
Times cited: 27
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America. 1999 Academic Article GET IT
Times cited: 13

more ...

less ...

Background

education and training

M.D. 96

M.D., University of Bucharest, Institute of Medicine & Pharmacology (Romania) 96

Contact

full name

Daniel C. Danila

VIVO Weill Cornell Medical College

Daniel C. Danila Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name